Aurora Cannabis and MedReleaf Australia announced the launch of CraftPlant, a new medical cannabis brand for patients in the Australian market. The CraftPlant brand includes three new products available for doctors to prescribe – Greendae, Navana and HiVolt. All three are developed from ultra-premium cultivars and are THC-dominant with high percentages of terpenes. The cultivars were developed by Occo, Aurora’s leading science and genetics business. The new range is produced under strict EU-GMP certified conditions and will be available in 10g containers. Aurora currently holds a 10% ownership stake in MedReleaf Australia, a fully licensed, private company. Together, they provide Australian patients with several Aurora-branded products, including dried flower, oils and soft gels.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACB:
- Here’s What You Missed in Cannabis This Week
- Largest borrow rate increases among liquid names
- Aurora Cannabis price target lowered to C$1.75 from C$2.25 at CIBC
- Aurora Cannabis price target lowered to C$1.50 from C$2 at Canaccord
- Aurora Cannabis price target lowered to C$1.50 from C$2.00 at Canaccord